Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

Stock Information for Vaxart Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Vaxart Inc.

Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
Vaxart to Participate in BTIG Biotechnology Conference 2026
Vaxart Announces Results of Annual Meeting of Stockholders
Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine
Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements
Vaxart Publishes Presentation Urging Shareholders to Vote "FOR" ALL Six of the Company's Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.